Musaffa Logo

Our certifications

Independent proof that every stock and portfolio meets halal standards.

How we screen every stock
METHODOLOGY

How we screen every stock

Our 5-step halal methodology, in 90 seconds.

AQST Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: May 21, 2026

Report Source: 2026 1st Quarter Report

Analyst's Ratings for Aquestive Therapeutics Inc (AQST)

Based on 15 analysts giving stock ratings to Aquestive Therapeutics Inc in the past 3 months

Strong
Sell
SellHoldBuyStrong
Buy
Strong Buy
27
Buy
66
Hold
7
Sell
0
Strong Sell
0
Aquestive Therapeutics Inc

Aquestive Therapeutics Inc. Stock Analysis AQST

United States Health Care Small Cap Report:
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 147 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. The company has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The firm also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The firm is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Read More

Aquestive Therapeutics Inc (AQST) Chart

Key Statistics of Aquestive Therapeutics Inc (AQST)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$4.71$5.11

Today's Open

$4.71

Volume

2.99M

P/E Ratio (TTM)

-

52 Week Range

$2.93$7.55

Market Cap

530.65M

Avg. Volume

1.66M

Dividend Yield

-

Financial Metrics & Statements of Aquestive Therapeutics Inc (AQST)

FAQ's for Aquestive Therapeutics Inc (AQST)

  • According to Musaffa’s Shariah screening methodology, Aquestive Therapeutics Inc (AQST) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
  • A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Aquestive Therapeutics Inc using these criteria to determine its compliance status.
  • Muslim investors may consider investing in Aquestive Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
  • Musaffa determines the Shariah status of Aquestive Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
  • The Shariah compliance status of Aquestive Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
  • Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
  • You can check the latest Shariah compliance status of Aquestive Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Disclaimer

The content provided on this website is intended solely for informational and educational purposes. Musaffa is a technology, data, education, and research company. We are not licensed financial service provider by the authorized relevant financial service regulator in India or any other regulatory government body, and we do not offer or facilitate any trading, brokerage, investment, or financial advisory services. We do not deliberately target an audience seeking financial services.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Musaffa of your own accord, and that there has been no form of solicitation, advertisement, or inducement by Musaffa or its members. Musaffa shall not be liable for the consequences of any action taken by relying on the material or information provided on this website. The contents of this website are the intellectual property of Musaffa.